The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Human Insulin Delivery System Market Research Report 2025
Synopsis
Human insulin delivery system is an alternative to multiple daily injections of insulin by insulin syringes or an insulin pen and allows for flexible insulin therapy when used in conjunction with blood glucose monitoring and carbohydrate counting for human being.
The global Human Insulin Delivery System market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Human Insulin Delivery System is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Human Insulin Delivery System is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Human Insulin Delivery System include BD, Novo Nordisk, Medtronic, Sanofi, ELI Lilly and Company, Ypsomed Holding, Animas Corporation, Tandem Diabetes Care and Insulet Corporation, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Human Insulin Delivery System, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Human Insulin Delivery System.
Report Scope
The Human Insulin Delivery System market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Human Insulin Delivery System market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Human Insulin Delivery System manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
BD
Novo Nordisk
Medtronic
Sanofi
ELI Lilly and Company
Ypsomed Holding
Animas Corporation
Tandem Diabetes Care
Insulet Corporation
Biocon
Roche
Johnson & Johnson
Microport
Segment by Type
Automatic
Manual
Segment by Application
Hospitals
Clinics
Homecare
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Human Insulin Delivery System manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Human Insulin Delivery System in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Human insulin delivery system is an alternative to multiple daily injections of insulin by insulin syringes or an insulin pen and allows for flexible insulin therapy when used in conjunction with blood glucose monitoring and carbohydrate counting for human being.
The global Human Insulin Delivery System market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Human Insulin Delivery System is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Human Insulin Delivery System is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Human Insulin Delivery System include BD, Novo Nordisk, Medtronic, Sanofi, ELI Lilly and Company, Ypsomed Holding, Animas Corporation, Tandem Diabetes Care and Insulet Corporation, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Human Insulin Delivery System, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Human Insulin Delivery System.
Report Scope
The Human Insulin Delivery System market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Human Insulin Delivery System market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Human Insulin Delivery System manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
BD
Novo Nordisk
Medtronic
Sanofi
ELI Lilly and Company
Ypsomed Holding
Animas Corporation
Tandem Diabetes Care
Insulet Corporation
Biocon
Roche
Johnson & Johnson
Microport
Segment by Type
Automatic
Manual
Segment by Application
Hospitals
Clinics
Homecare
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Human Insulin Delivery System manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Human Insulin Delivery System in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Human Insulin Delivery System Market Overview
1.1 Product Overview and Scope of Human Insulin Delivery System
1.2 Human Insulin Delivery System Segment by Type
1.2.1 Global Human Insulin Delivery System Market Value Comparison by Type (2024-2030)
1.2.2 Automatic
1.2.3 Manual
1.3 Human Insulin Delivery System Segment by Application
1.3.1 Global Human Insulin Delivery System Market Value by Application: (2024-2030)
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Homecare
1.4 Global Human Insulin Delivery System Market Size Estimates and Forecasts
1.4.1 Global Human Insulin Delivery System Revenue 2019-2030
1.4.2 Global Human Insulin Delivery System Sales 2019-2030
1.4.3 Global Human Insulin Delivery System Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Human Insulin Delivery System Market Competition by Manufacturers
2.1 Global Human Insulin Delivery System Sales Market Share by Manufacturers (2019-2024)
2.2 Global Human Insulin Delivery System Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Human Insulin Delivery System Average Price by Manufacturers (2019-2024)
2.4 Global Human Insulin Delivery System Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Human Insulin Delivery System, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Human Insulin Delivery System, Product Type & Application
2.7 Human Insulin Delivery System Market Competitive Situation and Trends
2.7.1 Human Insulin Delivery System Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Human Insulin Delivery System Players Market Share by Revenue
2.7.3 Global Human Insulin Delivery System Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Human Insulin Delivery System Retrospective Market Scenario by Region
3.1 Global Human Insulin Delivery System Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Human Insulin Delivery System Global Human Insulin Delivery System Sales by Region: 2019-2030
3.2.1 Global Human Insulin Delivery System Sales by Region: 2019-2024
3.2.2 Global Human Insulin Delivery System Sales by Region: 2025-2030
3.3 Global Human Insulin Delivery System Global Human Insulin Delivery System Revenue by Region: 2019-2030
3.3.1 Global Human Insulin Delivery System Revenue by Region: 2019-2024
3.3.2 Global Human Insulin Delivery System Revenue by Region: 2025-2030
3.4 North America Human Insulin Delivery System Market Facts & Figures by Country
3.4.1 North America Human Insulin Delivery System Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Human Insulin Delivery System Sales by Country (2019-2030)
3.4.3 North America Human Insulin Delivery System Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Human Insulin Delivery System Market Facts & Figures by Country
3.5.1 Europe Human Insulin Delivery System Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Human Insulin Delivery System Sales by Country (2019-2030)
3.5.3 Europe Human Insulin Delivery System Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Human Insulin Delivery System Market Facts & Figures by Country
3.6.1 Asia Pacific Human Insulin Delivery System Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Human Insulin Delivery System Sales by Country (2019-2030)
3.6.3 Asia Pacific Human Insulin Delivery System Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Human Insulin Delivery System Market Facts & Figures by Country
3.7.1 Latin America Human Insulin Delivery System Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Human Insulin Delivery System Sales by Country (2019-2030)
3.7.3 Latin America Human Insulin Delivery System Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Human Insulin Delivery System Market Facts & Figures by Country
3.8.1 Middle East and Africa Human Insulin Delivery System Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Human Insulin Delivery System Sales by Country (2019-2030)
3.8.3 Middle East and Africa Human Insulin Delivery System Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Human Insulin Delivery System Sales by Type (2019-2030)
4.1.1 Global Human Insulin Delivery System Sales by Type (2019-2024)
4.1.2 Global Human Insulin Delivery System Sales by Type (2025-2030)
4.1.3 Global Human Insulin Delivery System Sales Market Share by Type (2019-2030)
4.2 Global Human Insulin Delivery System Revenue by Type (2019-2030)
4.2.1 Global Human Insulin Delivery System Revenue by Type (2019-2024)
4.2.2 Global Human Insulin Delivery System Revenue by Type (2025-2030)
4.2.3 Global Human Insulin Delivery System Revenue Market Share by Type (2019-2030)
4.3 Global Human Insulin Delivery System Price by Type (2019-2030)
5 Segment by Application
5.1 Global Human Insulin Delivery System Sales by Application (2019-2030)
5.1.1 Global Human Insulin Delivery System Sales by Application (2019-2024)
5.1.2 Global Human Insulin Delivery System Sales by Application (2025-2030)
5.1.3 Global Human Insulin Delivery System Sales Market Share by Application (2019-2030)
5.2 Global Human Insulin Delivery System Revenue by Application (2019-2030)
5.2.1 Global Human Insulin Delivery System Revenue by Application (2019-2024)
5.2.2 Global Human Insulin Delivery System Revenue by Application (2025-2030)
5.2.3 Global Human Insulin Delivery System Revenue Market Share by Application (2019-2030)
5.3 Global Human Insulin Delivery System Price by Application (2019-2030)
6 Key Companies Profiled
6.1 BD
6.1.1 BD Corporation Information
6.1.2 BD Description and Business Overview
6.1.3 BD Human Insulin Delivery System Sales, Revenue and Gross Margin (2019-2024)
6.1.4 BD Human Insulin Delivery System Product Portfolio
6.1.5 BD Recent Developments/Updates
6.2 Novo Nordisk
6.2.1 Novo Nordisk Corporation Information
6.2.2 Novo Nordisk Description and Business Overview
6.2.3 Novo Nordisk Human Insulin Delivery System Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Novo Nordisk Human Insulin Delivery System Product Portfolio
6.2.5 Novo Nordisk Recent Developments/Updates
6.3 Medtronic
6.3.1 Medtronic Corporation Information
6.3.2 Medtronic Description and Business Overview
6.3.3 Medtronic Human Insulin Delivery System Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Medtronic Human Insulin Delivery System Product Portfolio
6.3.5 Medtronic Recent Developments/Updates
6.4 Sanofi
6.4.1 Sanofi Corporation Information
6.4.2 Sanofi Description and Business Overview
6.4.3 Sanofi Human Insulin Delivery System Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Sanofi Human Insulin Delivery System Product Portfolio
6.4.5 Sanofi Recent Developments/Updates
6.5 ELI Lilly and Company
6.5.1 ELI Lilly and Company Corporation Information
6.5.2 ELI Lilly and Company Description and Business Overview
6.5.3 ELI Lilly and Company Human Insulin Delivery System Sales, Revenue and Gross Margin (2019-2024)
6.5.4 ELI Lilly and Company Human Insulin Delivery System Product Portfolio
6.5.5 ELI Lilly and Company Recent Developments/Updates
6.6 Ypsomed Holding
6.6.1 Ypsomed Holding Corporation Information
6.6.2 Ypsomed Holding Description and Business Overview
6.6.3 Ypsomed Holding Human Insulin Delivery System Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Ypsomed Holding Human Insulin Delivery System Product Portfolio
6.6.5 Ypsomed Holding Recent Developments/Updates
6.7 Animas Corporation
6.6.1 Animas Corporation Corporation Information
6.6.2 Animas Corporation Description and Business Overview
6.6.3 Animas Corporation Human Insulin Delivery System Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Animas Corporation Human Insulin Delivery System Product Portfolio
6.7.5 Animas Corporation Recent Developments/Updates
6.8 Tandem Diabetes Care
6.8.1 Tandem Diabetes Care Corporation Information
6.8.2 Tandem Diabetes Care Description and Business Overview
6.8.3 Tandem Diabetes Care Human Insulin Delivery System Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Tandem Diabetes Care Human Insulin Delivery System Product Portfolio
6.8.5 Tandem Diabetes Care Recent Developments/Updates
6.9 Insulet Corporation
6.9.1 Insulet Corporation Corporation Information
6.9.2 Insulet Corporation Description and Business Overview
6.9.3 Insulet Corporation Human Insulin Delivery System Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Insulet Corporation Human Insulin Delivery System Product Portfolio
6.9.5 Insulet Corporation Recent Developments/Updates
6.10 Biocon
6.10.1 Biocon Corporation Information
6.10.2 Biocon Description and Business Overview
6.10.3 Biocon Human Insulin Delivery System Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Biocon Human Insulin Delivery System Product Portfolio
6.10.5 Biocon Recent Developments/Updates
6.11 Roche
6.11.1 Roche Corporation Information
6.11.2 Roche Human Insulin Delivery System Description and Business Overview
6.11.3 Roche Human Insulin Delivery System Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Roche Human Insulin Delivery System Product Portfolio
6.11.5 Roche Recent Developments/Updates
6.12 Johnson & Johnson
6.12.1 Johnson & Johnson Corporation Information
6.12.2 Johnson & Johnson Human Insulin Delivery System Description and Business Overview
6.12.3 Johnson & Johnson Human Insulin Delivery System Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Johnson & Johnson Human Insulin Delivery System Product Portfolio
6.12.5 Johnson & Johnson Recent Developments/Updates
6.13 Microport
6.13.1 Microport Corporation Information
6.13.2 Microport Human Insulin Delivery System Description and Business Overview
6.13.3 Microport Human Insulin Delivery System Sales, Revenue and Gross Margin (2019-2024)
6.13.4 Microport Human Insulin Delivery System Product Portfolio
6.13.5 Microport Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Human Insulin Delivery System Industry Chain Analysis
7.2 Human Insulin Delivery System Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Human Insulin Delivery System Production Mode & Process
7.4 Human Insulin Delivery System Sales and Marketing
7.4.1 Human Insulin Delivery System Sales Channels
7.4.2 Human Insulin Delivery System Distributors
7.5 Human Insulin Delivery System Customers
8 Human Insulin Delivery System Market Dynamics
8.1 Human Insulin Delivery System Industry Trends
8.2 Human Insulin Delivery System Market Drivers
8.3 Human Insulin Delivery System Market Challenges
8.4 Human Insulin Delivery System Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
